New research suggests that patients who discontinue popular slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who stop conventional lifestyle programs.
Research printed in a prominent medical journal demonstrates that while overweight individuals can lose substantial amounts of their body weight while on the medication, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such treatments should be informed of the danger of quick rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a return to starting mass within about one and a half years.
Weighing Therapies
The research, which examined 37 of trials involving over 9,000 of participants, compared the results of the injectable medications with other pills.
Scientists emphasize that people who shed pounds through lifestyle changes alone generally see a slower creep back—around 100 grams monthly—once they finish.
Understanding the Rapid Regain
Doctors believe the mechanism of the jabs is key to understanding the heightened weight return.
These medications imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing the hormone levels several times higher than normal may cause the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating much more probable."
A Chronic Condition?
Health authorities recommend the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, given the likelihood of relapse, the therapy should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who state that the results "emphasize the chronic nature of obesity," similar to managing conditions like high blood pressure.
User Accounts
People who have discontinued the jabs report a intense return of hunger.
"I experienced something flipping and you become starving," described an individual.
This challenge is worsened if users have not developed permanent dietary or behavioural modifications during therapy.
Widespread Interest
Survey data suggest that millions of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a permanent fix and maintained weight loss relies on integrated behavioural support.
